MYELOFIBROSIS (MF)
Clinical trials for MYELOFIBROSIS (MF) explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS (MF) trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS (MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for myelofibrosis patients: drug combo trial targets those failed by standard therapy
Disease control Recruiting nowThis early-stage trial tests a new drug called roginolisib combined with the standard drug ruxolitinib in 26 adults with myelofibrosis whose disease did not respond to approved JAK inhibitors. The main goal is to check the safety and tolerability of the combination. Researchers w…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE1, PHASE2 • Sponsor: iOnctura • Aim: Disease control
Last updated May 17, 2026 04:28 UTC
-
New drug trial hopes to tame rare blood cancers
Disease control Recruiting nowThis early-phase study tests a new drug called PRT12396 in about 100 people with polycythemia vera or myelofibrosis, which are types of blood cancers. The main goals are to find a safe dose and see if the drug can help control the disease. Participants must have a specific gene m…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
New combo aims to shrink spleen and ease symptoms in Hard-to-Treat myelofibrosis
Disease control Recruiting nowThis early-phase trial tests two drugs, tagraxofusp and pacritinib, together in about 20 adults with myelofibrosis (a bone marrow disorder) who have already tried standard JAK inhibitors or cannot take them. The main goals are to see if the combination can shrink an enlarged sple…
Matched conditions: MYELOFIBROSIS (MF)
Phase: EARLY_PHASE1 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated May 17, 2026 04:14 UTC
-
New drug aims to reverse bone marrow scarring in rare blood cancer
Disease control Recruiting nowThis study tests if pacritinib can reduce bone marrow fibrosis (scarring) in 30 adults with myelofibrosis who also have low platelet counts. Participants take the drug for up to 2 years, and doctors check bone scarring and spleen size using biopsies and MRI. The goal is to see if…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE2 • Sponsor: Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo therapy aims to tame rare blood cancers
Disease control Recruiting nowThis study tests a new drug, axatilimab, alone and with the standard drug ruxolitinib, in people with myelofibrosis (MF) or chronic myelomonocytic leukemia (CMML). The goal is to find a safe dose and see if the combination helps control the disease. About 66 adults who have alrea…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Could a $10 arthritis pill tame rare blood cancers?
Disease control Recruiting nowThis study tests whether low-dose methotrexate (MTX), a safe and inexpensive drug used for decades in arthritis, can help people with certain blood cancers called myeloproliferative neoplasms (MPNs). The trial will enroll 54 adults with polycythemia vera, essential thrombocythemi…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
Could a simple blood test and scan replace painful bone marrow biopsies for myelofibrosis patients?
Diagnosis Recruiting nowThis study is testing a new method to detect and track bone marrow scarring (fibrosis) in people with myelofibrosis without needing a painful bone marrow biopsy. Researchers will use a blood test and a special PET scan tracer that targets a protein called CCR2, which is linked to…
Matched conditions: MYELOFIBROSIS (MF)
Phase: NA • Sponsor: Azienda Ospedaliero-Universitaria di Parma • Aim: Diagnosis
Last updated May 13, 2026 16:03 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study follows 5,000 adults with myeloproliferative neoplasms (MPNs) — rare blood cancers — to understand how symptoms change and how the disease progresses over years. Participants share their health records, insurance data, and regular surveys about how they feel. No new tr…
Matched conditions: MYELOFIBROSIS (MF)
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 04, 2026 16:17 UTC